# Yoshiya Tanaka

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yoshiya-tanaka/

## Facts

| Field | Value |
| --- | --- |
| Citations | 57,260 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 104 |
| i10-index | 751 |
| Last Known Institution | Target (United States) |
| OpenAlex ID | https://openalex.org/A5015953107 |
| ORCID iD | 0000-0002-0807-7139 |
| Works | 1,683 |

## Researcher papers

Showing 12 of 18.

- [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/)
- [Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011](https://scholariq.org/papers/comprehensive-diagnostic-criteria-for-igg4-related-disease-igg4-rd-2011/)
- [Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011](https://scholariq.org/papers/comprehensive-diagnostic-criteria-for-igg4-related-disease-igg4-rd-2011-2/)
- [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology-2/)
- [Trial of Anifrolumab in Active Systemic Lupus Erythematosus](https://scholariq.org/papers/trial-of-anifrolumab-in-active-systemic-lupus-erythematosus/)
- [EULAR recommendations for the management of systemic lupus erythematosus: 2023 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023/)
- [Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis](https://scholariq.org/papers/baricitinib-versus-placebo-or-adalimumab-in-rheumatoid-arthritis/)
- [T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ](https://scholariq.org/papers/t-cell-adhesion-induced-by-proteoglycan-immobilized-cytokine-mip-l/)
- [A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details](https://scholariq.org/papers/a-novel-clinical-entity-igg4-related-disease-igg4rd-general-concept-and-details/)
- [A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details](https://scholariq.org/papers/a-novel-clinical-entity-igg4-related-disease-igg4rd-general-concept-and-details-2/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial](https://scholariq.org/papers/baricitinib-for-systemic-lupus-erythematosus-a-double-blind-randomised-placebo/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Target (United States)](https://scholariq.org/institutions/target-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.